



08-25-03

Attorney Docket No. 037003-0280732

Client Ref. No. 2000-30-0261VUS

1642

PHS

RECEIVED
AUG 27 2003
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Nabil

Serial No: 09/986,174

Filed: November 7, 1991

Title: BISPECIFIC FUSION PROTEIN
AND METHOD OF USE FOR
ENHANCING EFFECTOR CELL
KILLING OF TARGET CELLS

) Examiner: To be assigned

) Art Unit: 1642

) Certificate of Mailing Under §1.10) I, Patricia Munoz, hereby certify that this paper
) or fee is being deposited with the United States
) Postal Service as Express Mail Post Office to
) Addressee service, Express Mailing Label No.
) EV 304 112 164 US, under 37 C.F.R. § 1.10 on
) the date indicated below and is addressed to the
) Commissioner for Patents, P.O. Box 1450,
) Alexandria, VA 22313-1450 on this date.

) Date: August 21, 2003

By: Patricia Munoz

INFORMATION DISCLOSURE STATEMENTCommissioner for Patents
Post Office Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the Applicants' duty under 37 C.F.R. §§1.97-98, the following information is brought to the attention of the Examiner. The items are listed on the attached form PTO-1449 and copies of the references are attached for the Examiner's convenience.

Certain of these references were cited in the Supplementary Partial European Search Report for European Application No. 01939954.2, which is related to the present application in that it claims priority from, *inter alia*, an earlier filed International application. A copy of the Supplementary Partial European Search Report is attached.


The items identified in this Information Disclosure Statement may or may not be "material" pursuant to 37 CFR §1.56 and the submission thereof by Applicants shall not be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 C.F.R. §1.97(h)), or even qualifies as "prior art" under 35 U.S.C. §102 with respect to this invention unless specifically designated by Applicants as such.

The filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information, as defined in 37 C.F.R. §1.56, exists.

Applicant believes that no fee is due. However, the Commissioner is hereby authorized to charge any such fee, including any fee due with this submission, if the attached check(s) is in the wrong amount or otherwise improper or missing, in connection with this and the attached papers, or with this application during its entire pendency to or to credit any overpayment to Deposit Account 03-3975, Order No. 037003-0280732.

Respectfully submitted,

Date: August 21, 2003



Suzanne L. Biggs
Registration No. 30,158 for

Thomas A. Cawley, Jr.
Registration No. 40,944
PILLSBURY WINTHROP LLP
1600 Tysons Boulevard
McLean, VA 22102
Telephone: (703) 905-2000
Fax Line: (703) 905-2500
Direct Line: (858) 509-4095

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office



Atty. Dkt. No.	M#	Client Ref.
	037003-0280732	2000-30-0261VUS

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Applicant: Nabil	
Appln. No.: 09/986,174	
Filing Date: November 7, 2001	
Examiner: To be assigned	Group Art Unit: 1642

Date: August 20, 2003

Page 1 of 1

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR 5,736,137	04/1998	Anderson, et al.	424	133.1	
	BR 5,776,456	07/1998	Anderson, et al.	424	133.1	
	CR 5,843,439	12/1998	Anderson, et al.	424	133.1	
	DR					
	ER					
	FR					
	GR					

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
					Enclosed	No	Enclose	No
HR	0 396 387 A2	11/1990	EP	Rosenblum, et al.				
IR								
JR								
KR								
LR								
MR								

RECEIVED

AUG 27 2003

TECH CENTER 1600/2900

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

NR	Ozello, et al., Experimental immunotherapy of breast cancer using alpha interferon conjugated to monoclonal antibody Mc5, <i>Advances in Experimental Medicine and Biology</i> , Spring St., NY, US, vol. 353, 1994, pages 35-46				
OR	Ozello, et al., Conjugation of interferon alpha to a humanized monoclonal antibody (HuBrE-3v1) enhances the selective localization and antitumor effects of interferon in breast cancer xenografts, <i>Breast Cancer Research and Treatment</i> , 48:135-147 (1998)				
PR	Pallela, et al., Interferon-α-2b immunoconjugate for improving immunoscintigraphy and immunotherapy, <i>The Journal of Nuclear Medicine</i> , 41(6):1108-1113 (2000)				
QR					
RR					
SR					

Examiner	Date Considered:
----------	------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.